VC-backed BioSciences goes public
Durham, North Carolina-based Precision BioSciences, a genome editing system provider, has raised $126.4 million for its IPO after pricing its 7.9 million shares at $16 per share. The stock began trading March 28, 2019 on the NASDAQ under the ticker symbol "DTIL." JP Morgan, Goldman Sachs, Jefferies and Barclays are the underwriters. Precision BioSciences' pre-IPO backers include ArrowMark Partners, Franklin Templeton Investments, Cowen Healthcare Investments, Brace Pharma Capital, Adage Capital Management, Cormorant Asset Management, Gilead Sciences, Vivo Capital, Alexandria Venture Investments, Ridgeback Capital, Agent Capital, Leerink Partners, venBio, F-Prime and Osage University Partners.
28 March 2019•3 mins read
